Kaitlyn D’Onofrio

DocwireNews

AbbVie&rsquo;s blockbuster <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/taltz-vs-cosentyx-how-do-these-rheumatic-drugs-compare/">arthritis drug</a> Humira&reg; (<a href="https://www.docwirenews.com/docwire-pick/fda-approves-biosimilar-adalimumab/">adalimumab</a>) took the number one spot on a list of seven drugs <a href="https://www.reuters.com/article/us-usa-healthcare-drugpricing/humira-rituxan-top-list-of-u-s-drugs-with-biggest-price-increases-report-idUSKBN1WN1BE">collectively responsible</a> for a $5.1 billion jump in U.S. medical spending, despite the fact that no new research or evidence over the past three years has supported these increased prices, <a href="https://icer-review.org/wp-content/uploads/2019/01/ICER_UPI_Final_Report_and_Assessment_100819_Final.pdf">according to a new report</a>.The net change in the price of Humira increased by 15.9%, which equated to a $1.857 billion increase in spending. Humira&rsquo;s 2018 sales revenue also largely outpaced that of other drugs at $13.685 billion&mdash;a 19.1% eight quarter wholesale acquisition cost (WAC) change. 2018 sales revenue for the second drug on the list, Revlimid&reg;, was $6.469 billion.The &ldquo;Unsupported Price Increase Report&rdquo; was published by the Institute for Clinical and Economic Review (ICER) on Oct. 8.&ldquo;The norm in the United States has been for most pharmaceutical manufacturers to increase prices year after year&mdash;even accounting for the discounts they give insurers, and even for drugs that already sit at the top of the chart of spending for drugs in the US,&rdquo; said David Rind, MD, chief medical officer of ICER, <a href="https://icer-review.org/announcements/icer-identifies-costliest-us-drug-price-hikes-that-are-not-supported-by-new-clinical-evidence/">in a press release</a>. &ldquo;The goal of ICER&rsquo;s new [Unsupported Price Increase] report is to provide the public and policymakers an explicit and independent approach to determine whether price increases could potentially be supported by new clinical evidence. If new evidence emerges that shows a treatment may be more beneficial than what was previously understood, perhaps that new evidence could warrant some level of price increase. For seven of the nine drugs we reviewed, however, we found that the price increases lacked justification in new evidence.&rdquo;<h2>Humira: Price Hikes Not Supported by Clinical Evidence</h2>Humira garnered Food and Drug Administration (FDA) approval in 2002 and is indicated for the treatment of <a href="https://www.docwirenews.com/abstracts/rheumatology-abstracts/effectiveness-tolerability-and-safety-of-tofacitinib-in-rheumatoid-arthritis-a-retrospective-analysis-of-real-world-data-from-the-st-gallen-and-aarau-cohorts/">rheumatoid arthritis</a> (<a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/rheum-round-up-taltz-vs-cosentyx-rituximab-original-vs-biosimilar-and-more/">RA</a>), psoriatic arthritis (PsA), ankylosing spondylitis, juvenile idiopathic arthritis, adult and pediatric Crohn&rsquo;s disease, ulcerative colitis, <a href="https://www.docwirenews.com/docwire-pick/risankizumab-moderate-plaque-psoriasis/">plaque psoriasis</a>, adult and adolescent hidradenitis suppurativa, and adult and pediatric noninfectious uveitis. According to ICER&rsquo;s report, the treatment indications that constitute more than 10% of the drug&rsquo;s use are RA, PsA, adult Crohn&rsquo;s disease, ulcerative colitis, and plaque psoriasis.For the ICER report, all data spanning Jan. 1, 2016, and Dec. 31, 2018, on the safety and clinical effectiveness of Humira were taken into consideration. This included 204 references (160 conference presentations and 44 published manuscripts) provided by the manufacturer; ICER did not conduct an additional search for evidence.&ldquo;However, none [of the submitted references] met our inclusion criteria of new information on benefits and/or harms within the indications that account for greater than 10% of use,&rdquo; according to the report. The reasons why the studies were not eligible for inclusion were, according to ICER (some studies met more than one criteria but were grouped into one category):<ul>
<li>Study design does not meet our criteria for assessing efficacy (e.g., single arm study) (n = 76)</li>
<li>Intervention/comparison outside our scope (TNF inhibitors vs. non-TNF inhibitors) (n = 62)</li>
<li>Previously known information about adalimumab (e.g., efficacy of adalimumab vs. placebo in plaque psoriasis) (n = 28)</li>
<li>Outcomes not relevant to our scope (e.g., cost-effectiveness analysis) (n = 25)</li>
<li>Adalimumab in all comparison arms (n = 6)</li>
<li>Abstract &ndash; limited information on study design (n = 5)</li>
<li>Indication accounts for less than 10% of use (e.g., nail psoriasis) (n = 2)</li>
</ul>The third drug on the list of those who contributed to the significant increase in medical spending was Lyrica&reg; (pregabalin), which treats pain caused by fibromyalgia.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Humira® No. 1 Drug Linked to $5.1 B Increase in Medical Spending

Rheumatology

AbbVie’s blockbuster arthritis drug Humira® (adalimumab) took the number one spot on a list of seven drugs collectively responsible for a $5.1 billion jump in U.S. medical ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe